ExSight Capital, Partner Firas Rahhal, MD, Are Building a Successful Record as Impact Investor

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 156″]

With $3 million to invest in first-time funds, impact investor ExSight Capital built a promising and productive portfolio that included gene therapy company RetroSense. Now, ExSight co-founder and partner Firas M. Rahhal, MD, says the firm is planning to raise a much larger fund that could elevate its standing as a seed-stage investor in ophthalmology companies.

Learn more about Firas M. Rahhal, MD here.